April 18, 2019 / 9:44 AM / 3 months ago

BRIEF-Almirall: NICE In UK Gives Final Recommendation For Co's Drug To Treat Plaque Psoriasis

April 18 (Reuters) - Almirall SA:

* SAID ON WEDNESDAY THAT NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) IN UK HAD PUBLISHED ITS FINAL RECOMMENDATION FOR ILUMETRI (TILDRAKIZUMAB) AS A COST-EFFECTIVE OPTION TO TREAT MODERATE-TO-SEVERE PLAQUE PSORIASIS

* TILDRAKIZUMAB WAS APPROVED BY THE EUROPEAN COMMISSION IN SEPTEMBER 2018, IS ALREADY AVAILABLE IN GERMANY AND IS DUE TO BE MARKETED IN ALL EU MEMBER STATES

* ILUMETRI RECEIVED A PROVISIONAL APPROVAL FROM NICE ON MARCH 8

Source text: bit.ly/2UqlTZo

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below